Tapish Chandwaskar

[Nikhil saini @iNikhilsaini]

No festival in the world can match the aesthetics of Diwali. Truly the most beautiful festival on this planet! #Diwali

[Prashant Sharma @RiskRewardRider]

Q2 FY27 EARNINGS SEASON: EXCELLENT & BRILLIANT PERFORMERS!

From HFCL and E2E Networks to Hindustan Zinc, BHEL, Laurus Labs and CDSL, several companies have reported impressive revenue and profit growth. Which stocks deserve a closer look?

#Q2Results #EarningsSeason #IndianStockMarket #StocksToWatch #Nifty50 #RiskRewardRider

[Ashish Malani @malani4u]

Sahajanand Medical Technologies (SMT): From a Vision in Surat to a Potential Billion-Dollar Global MedTech Company.

Thanks to @arvind_kothari @niveshaay , had the chance to meet the management and interact with them before ipo at The Dhando Valley.

Lets start with the story!

In the late 1990s, when India was largely dependent on expensive imported cardiac stents, an entrepreneur from Surat saw an opportunity to change that.

Dhirajlal Kotadia, an engineer and entrepreneur who had already built a successful precision-engineering and laser-technology business serving the diamond industry, believed India could manufacture world-class cardiovascular devices at affordable prices.

The vision was ambitious: develop life-saving medical technology in India, reduce dependence on imported devices and make advanced cardiac treatment accessible to more patients.

That vision led to the creation of Sahajanand Medical Technologies, whose origins go back to 1999 and which was incorporated in 2001.

What started with coronary stents has evolved into something much bigger.

Over the next 25 years, SMT invested heavily in research, clinical trials, product development and international expansion.

Today, the company has:

Presence across 77 countries
Approximately 25% share of India’s drug-eluting stent market by volume
119 granted patents and 78 pending patent applications
75 clinical studies, including 66 completed
Manufacturing capabilities across India and Thailand
Products spanning coronary stents, balloons, occluders and transcatheter heart valves

The company has also transitioned to its next generation of leadership, with Bhargav Kotadia taking over as CEO in April 2025.

But what interests me most is the economics of this 25-year journey.

My reconstruction of SMT’s historical filings suggests that the company has spent approximately(min) ₹950 crore cumulatively on R&D and clinical development, with ₹631 crore identifiable across disclosed financial periods.

In today’s purchasing-power terms, that historical R&D investment could be worth approximately ₹1,300 crore.

Add acquisitions, international distribution, manufacturing infrastructure and the time required to establish clinical credibility, and the barriers to recreating this business become significant.

Despite all this investment, SMT currently operates at only around 14% consolidated EBITDA margins.

Europe, now its largest market, has only recently reached operating breakeven, while India and the Rest of the World already operate above 20% EBITDA margins.

This raises an interesting question.

What happens when a company that has spent 25 years developing technology, products and global distribution finally starts monetising those investments at scale?

At ₹2,000 crore revenue and 20–25% EBITDA margins, SMT could potentially generate ₹400–500 crore EBITDA, compared with ₹171 crore in FY26.

And the company is no longer dependent only on coronary stents. Structural Heart, TAVI, occluders, drug-coated balloons and next-generation devices could provide the next leg of growth.

I spent time studying SMT’s RHP, its older DRHPs, acquisition history, R&D spending, product pipeline and global cardiovascular markets.

Here is my detailed thesis on why Sahajanand Medical Technologies could become one of India’s most interesting global MedTech businesses.

A deep dive into SMT’s business, R&D moat, acquisitions, products, margins and what could change over the next 3–5 years.

1. First, understand the business.

SMT is much more than an Indian coronary stent manufacturer.

It operates across two major categories:

* Vascular Intervention: Coronary stents, balloons and related devices.
* Structural Heart: TAVI valves, occluders and other devices.

FY26 revenue: ₹1,211 Cr
EBITDA: ₹171 Cr
EBITDA margin: 14.1%
PAT: ₹69 Cr

The business is already global, but profitability could be at an inflection point.

[Pradip Kumbhani @1hangover_pk]

Every robot needs about 30 Motors and Every motor needs a magnet which are runs on a rare earth magnet.
Dysposium and Terbium are rare earth which controlled by China entirely.
Indian Entity which are related
- Midwest LTD
- Permenant Magnet
- Sona BLW
- PTC
- Deccan Goldmine

[SME Alpha @Rahulsingh36167]

Few Hot SME performance tracker -

FY26 Target Achievement vs FY27 Guidance 🔍

• FY26 performance & target achievement
• FY27 revenue growth ambitions
• Will management deliver again? 🚀
• Invest carefully. DYOR ⚠️

#SMEStocks #SmallCaps #FY27 #RevenueGrowth #DYOR

[RajStockWatch @RajStockWatch]

SHEET 3 TABLE HERE

[RajStockWatch @RajStockWatch]

Sheet -2

SHANTI INORGANICS
COMPLETE SPORTS & MANAGEMENT INDIA
KWICK FORENSIC SOLUTIONS
TECHNOCRATS PLASMA SYSTEMS
CREDENT CONNECT N CARE
ANAWIL WIRE & ENGINEERING
POOJA PRECISION ENGINEERING
SILVERSTORM PARKS & RESORTS
METALIC TECHNOFORGE
SOTEFIN BHARAT
MILLWORKS TECHNOLOGIES
DEVSON CATALYST
KRATIKAL TECH
ATHARVA POLYPLAST
SHREEDHAR SPINNERS
AVIENCE BIOMEDICALS

Sheet 3 in Thread below. 2/3

[RajStockWatch @RajStockWatch]

🌟🌟LIST OF GOOD SME IPOs LISTED FROM 01 Jan 2026 (Sheet 1, Sheet 2 & Sheet 3)

🗒️Data Covers: IPO Price, IPO P/E, List Price, Current Price, Current P/E, % Gain with respect to IPO Price. For most recent stocks, Capex Completion target time is given in Comments.

🩷LIKE, SAVE in 🔖BookMarks for Detailed Study

Some stocks start discounting future earnings , very early, considering capex. But not all. If price is still at lower valuation, BUT major capex is ongoing, it's an opportunity to track and enter, when price action starts. 👍

Suggest not to take Promoter's every word in Investor presentations, as Ved Vakya. Lot of fluff and inaccurate stuff will be there in their talks. 👎

Please go through recent NSE order announcements / capex status / business updates too before investing.👍

Do note , even some of these stocks could fail, 👎since we are yet to see First Post-Listing Financials. And there can be cooked up 👎revenue and extra high margins which could disappear with H1 result. So one has to track results closely. No blind bets.

SHEET 1
ACME INDIA INDUSTRIES
TNA SOLUTIONS
EVERESTIMS TECHNOLOGIES
SJP ULTRASONICS
VANS ELECTROENGINEERING
ACME UNIVERSAL SAFEZONE 9
ROOPA SCREEN
POOJA LOGISTICS
FX MULTITECH
ROBOKIDZ EDUVENTURES
SPECTRAA TECHNOLOGY SOLUTIONS
RAKSAN TRANSFORMERS
MAHARAJA & SPEEDEX INDIA
AMTECH ESTERS
QUALIANCE INTERNATIONAL
ASHUTOSH FIBRE
🩷LIKE, SAVE in 🔖BookMarks for Detailed Study

Sheet 2 and Sheet 3 in Thread below 1/3

[Tapish Chandwaskar @tapish10100]

@iMicrocap Source ?

[Tapish Chandwaskar @tapish10100]

@ashish_munjal .. 👍🏻 ta by

[Shreenidhi P @nid_rockz]

Manipal Payment and Identity Solutions
#MPIManipal

Inv PPT:

Increasing opportunity size in all segments
Increasing exports
Geographical diversification

Q1FY27:
Rev at 419cr⏫48% YoY
⏫23% QoQ

EBITDA at 124cr⏫44% YoY
⏫32% QoQ

OPM at 30%

PAT at 78cr⏫129% YoY
⏫37% QoQ

International business at 15.3% vs 3.9% of revenues

Core business compounding :
Govt ID and kiosk programs

International business scaling up:
5 regions
APAC,ME,Africa,UK&Europe,Americas
Nigeria bureau fully operational and certified

Emerging engines scaling up:
Growing at 2.3x
Metal card portfolio expanding with 10+ varaunta across top issuers
Tax stamps win adds multi year Long term revenue

Q1FY27 had 7.7cr incremental costs as seeding and development costs for new initiatives

FY23–FY26: strong growth, rising profitability and high returns with zero leverage

Opportunity size:

Identity Solutions: 1 Bn+ national ID cards delivered – taking the India model to emerging markets

International business: from ~1% of revenue in FY23 to 15.3% in Q1 FY27

Metal Cards: patented, Make-in-India premium cards – supplying all top-4 Indian issuers and exporting globally

Tax stamps: 30–35 Bn excise labels a year, ready to scale beyond India

RFID & IoT: item-level tagging for global retail majors, in a ~₹2.8 lakh cr global market by FY30

[Tapish Chandwaskar @tapish10100]

@shreytxt @YourbroRishabh Is base ipad m16 useful for normal surfing and reading stuffs ?

[Tapish Chandwaskar @tapish10100]

@maheshbarmer407 @saaaanjjjuuu Yes same question , and on which platform it is available ??

[Tapish Chandwaskar @tapish10100]

@Vismaya9999 Heg Advanced

[Satpal Singh @vsvicky_]

Kross 🔥

Extrusion Beam is the new growth lever

India’s first company to commission a single-piece axle beam, it's a superior product

[The Loggical Investor @logical_traderr]

Hey folks, The love you showed on my last newsletter (where we decoded the Aerospace value chain) was honestly overwhelming. Thank you for that 🙏

Now sharing another newsletter possibly my last one for this year , deep-diving into a company operating in the same space.

📌Unimech Aerospace & Manufacturing Ltd: A Business That Forces You to Think in Probabilities
https://t.co/ULgxWJHJNO

What’s inside the newsletter :

- Aerospace sector overview & India’s role
- How Unimech makes money
- Capacity, capabilities & moats
- Growth triggers & management guidance
- Risks + some investing wisdom I’ve learned

The newsletter is live. Do give it a read and share any feedback good or bad.
It genuinely helps me improve my writing skills.

Tags : @EquityValueIn @tusharbohra @caniravkaria @EquityInsightss @Anvith_ @selvaprathee
@soicfinance @ishmohit1
#Aerospace #precisioncomponents #Unimech

[Palak Shah @palakshahjourno]

India Sold its Biggest Geopolitical Weapon at a Discount

Are some bureaucrats in New Delhi selling the country's most strategic asset cheap?

Story Behind Hindustan Copper Stake Sale

https://t.co/Md60QF4Jf1

[Tapish Chandwaskar @tapish10100]

@abhishekcjain True 🫡

[Tapish Chandwaskar @tapish10100]

@investor_sr33 The BIG DADDY of all : MTAR Tech..

[Tapish Chandwaskar @tapish10100]

@dhruvbajaj184 👍👍🫡🫡🫡👏👏👏